X-82
AssetAlso called X-82 tablets
Dual inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor kinases
- Stage
- Phase 2, discontinued
- Modality
- Small molecule
- Target
- PDGFRB
- 9
- Indications
- 3
- Trials
- 1
- Developer
Trial NCT02348359 terminated on Jan 12, 2018: Interim analysis found study had achieved primary objective. No trial still running and nothing reported since. clinicaltrials.gov
Indications
9Age-related macular degeneration
Phase 2, Terminated, NCT02348359, clinicaltrials.gov, Oct 31, 2026
Exudative age-related macular degeneration
Phase 2, Terminated, NCT02348359, clinicaltrials.gov, Oct 31, 2026
Eye disease
Phase 2, Terminated, NCT02348359, clinicaltrials.gov, Oct 31, 2026
6 more
In the full profile
- Target and mechanism5
- Owner and partners1
- Trials3
- Evidence for its targets5
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.